RenovoRx Inc publishes investor presentation highlighting RenovoCath commercialization and cancer therapy platform
Reuters
Oct 07
<a href="https://laohu8.com/S/RNXT">RenovoRx Inc</a> publishes investor presentation highlighting RenovoCath commercialization and cancer therapy platform
RenovoRx Inc. has released a corporate overview highlighting the initial commercialization of its FDA-cleared RenovoCath® device in 2025, with first half revenues exceeding expectations. The company reports that 13 cancer centers have been approved to purchase RenovoCath, with four centers currently using the device with patients as of August 14, 2025. Discussions are ongoing with over 20 additional potential customers. RenovoRx estimates a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with the possibility for expanded applications and a total addressable market in the billions of dollars. The device is protected by patents until 2038 and is part of RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to address challenges in delivering therapy to tumors with poor blood supply, such as pancreatic cancer. The company is led by a team with expertise in clinical development and commercial execution in the pharma and medical device sectors. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/A48C6FE2189AC2D45C309FD23D340855EBF64206)
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.